Historically, though, it hasn’t always been easy for Black Americans to gather at the beach. Because of segregation and Jim Crow laws, Black residents were shut out from enjoying beaches ...

Atlanta is no longer a majority-Black city and it is not alone. A new report shows Atlanta is a hotspot for extreme gentrification. Over the past five decades, a mass infiltration of new residents ...

From tailored jackets and silk ties to playful fedoras and pocket squares, Black dandyism isn’t just a campy style—it has served as a powerful political act throughout history. Black dandyism ...

May 25 marks five years since George Floyd, an unarmed Black man, was killed by a White police officer in Minneapolis. The officer, Derek Chauvin, was found guilty on charges of murder and ...

Nowhere is this clearer than in the story of Black American tailoring and the legacy of the Black dandy. Inspired by scholar Monica L. Miller’s groundbreaking book Slaves to Fashion: Black ...

This year’s Met Gala is honoring Black fashion for the first time in its 77-year history. It’s an indirect celebration to be sure. Although the Costume Institute’s Spring 2025 exhibition ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Novartis announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded clinical-stage biopharmaceutical company focused on developing microRNA ...

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced some great news today, which is that it would be acquired by Novartis AG (NVS) for $7 per share in cash. However, there is room for additional ...

Novartis' established global development and commercial capabilities will enable this important new medicine to reach patients if approved," said Jay Hagan, CEO of Regulus Therapeutics.

Novartis has agreed to acquire Regulus Therapeutics for a total equity value of up to roughly $1.7 billion. With the merger, the Swiss pharmaceutical company aims to bring to more patients ...